The US FDA's approval of CSL's ANDEMBRY (garadacimab) for hereditary angioedema provides another opportunity to compare patient access to innovative treatments in the US and Australia. …
One CSL innovation that allows for a direct and timely comparison
June 18, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
Georgia Forrest
New Stories
-
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News -
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL presses ahead with transformation as earnings slip and leadership changes
February 11, 2026 - - Latest News -
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 - - Latest News -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News